SIRPA and neoplasm: Therapies that block the interaction of CD47 and SIRPα have been shown to stimulate tumour cell phagocytosis in vitro and induce anti-tumour immune responses in vivo [4,5,8,9], and CD47 blockade is being tested in clinical trials [10].